Replies to post #242708 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Point is , don’t you think BP’s were threatened by KITE or JUNO and others , why have they singled out NWBO ? That argument doesn’t make sense . Part of the blame for lack of credibility and lack of buyers does fall on management whether you want to believe it or not .

[survivor1x]

The smoking gun was the trial hold and then the tight lip coupled with comments from "self anointed biotech experts" followed by dilution. So.. while some of the share price drop is warranted from the smoke (that I do not believe is a fire), I think we can get back a ton of market share and when comparing to Kite and Juno 10B should be even close if we consider direct in multiple tumor types.

They have learned and patented methods that go above and beyond whether DC Vax can delay GBM. The insight into the inter workings of the human immune system and how to illicit a change with a patent-able method are worth MULTIPLES.

[exwannabe]

KITE and JUNO were both $10B market caps and less far along then NWBO

This has been posted here dozens of time. And it is still wrong.

Gillead bought Kite at the end of Aug '17. Yescarta already had completed it's pivotal trial had a BLA in progress. Approved mid Oct.

Celgene bought JUNO in Jan '18. JUNO's initial CAR-T flamed out, but their second gen effort completed it's pivotal and had results in late '17.